Investors: Press Releases

  • All
  • Non-Regulatory
  • Regulatory
Regulatory

Allarity Therapeutics issues new shares to Aalto Capital in connection with services rendered

Regulatory

Allarity Therapeutics Draws Down the Third Tranche Under Its Convertible Note Agreement with Negma Group LTD and Park Partners GP

Regulatory

2020 in Review: A Letter from Allarity’s CEO

Regulatory

Allarity Therapeutics Expands its Stenoparib License Rights to Include Anti-Viral Uses

Regulatory

Allarity Therapeutics Publishes Interim Report for the Period January – September 2020

Non-Regulatory

Allarity Therapeutics Invites Investors for Q3 2020 Report Conference Call

Regulatory

Allarity Therapeutics Draws Down the Second Tranche Under Its Convertible Note Agreement with Negma Group LTD and Park Partners GP

Regulatory

Allarity Therapeutics Hires New Chief Financial Officer

Regulatory

Allarity Therapeutics Gains Allowance from U.S. Patent and Trademark Office for New DRP® Biomarker Patents

Regulatory

Allarity Therapeutics Provides Update on Dovitinib Program

Regulatory

Allarity Therapeutics will trade under new short name ALLR starting on 12 October 2020

Regulatory

Press Release Allarity Therapeutics Shareholders Approve Company Name Change and Board Appointments

Regulatory

Press Release Oncology Venture A/S Issues 1,619,912 Shares in Exchange for Previously Annulled Warrants

Regulatory

Press Release Oncology Venture calls third investment tranche under its share subscription agreement with Global Corporate Finance

Regulatory

Press Release Oncology Venture Plans Name Change to Allarity Therapeutics and Board Restructuring to Align with Current Company Strategy

Regulatory

Notice to Convene an Extraordinary General Meeting

Regulatory

Press Release Oncology Venture Publishes Interim Report for the Period January – June 2020

Regulatory

Press Release Oncology Venture’s Novel PARP Inhibitor Stenoparib (formerly 2X-121) Shows Anti-Viral Activity Against Coronavirus in Pre-Clinical Studies

Non-Regulatory

Oncology Venture A/S Invites Investors for Q2 2020 Report Conference Call

Regulatory

Press Release Oncology Venture calls second investment tranche under its share subscription agreement and issues 5,980,020 shares to Global Corporate Finance

Oncology Venture is now

Allarity Therapeutics

At Allarity Therapeutics, we are defining a bright future for patients in a new paradigm of precision cancer treatments. Our mission is to bring clarity to personalized oncology medicines, marrying innovative therapies and superior companion diagnostics, to help fully realize the promise of personalized cancer care.

Allarity Therapeutics Logo